The 9MMPolyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a subclass of Juvenile Idiopathic Arthritis, which is the most common form of arthritis in children especially under the age of 16. PJIA is characterized by inflammation in five or more joints during the first six months of the disease. In rare cases, children with PJIA may also have concurrent psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches on the skin.
Report has covered granular-level analysis in each mapped market
In United States nearly 350,000 diagnosed with JIA
Polyarticular Juvenile Idiopathic Arthritis (PJIA) affects approximately 30% of children with arthritis and it is found more common in girls than boys
about 1 in 4 children with JIA have PJIA
Treatment Landscape:
Currently, market is dominated by mix type of therapy which includes, Drugs (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs, Biologic Response Modifiers and others), Physical Therapy, Occupational Therapy, Lifestyle Modifications)
Polyarticular Juvenile Idiopathic Arthritis (PJIA) market is struggling to get an effective treatment
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each drug type
Report has examined the how many and what type of cases refer to which type of therapy based on experts opinion analysis.
Several pipeline assets are under investigation, and expected to witness the market during the forecast period.
Report also provided promising therapy assessment including drugs, existing therapies and upcoming therapy
Novel drug target assessment
Expected launch of key pipeline assets
Promising molecules advantages offer over existing therapy
Impact assessment of pipeline assets
Drug analogue analysis
Expected annual cost of therapy
Market Segmentation Analysis by:
By Case Type:
Rheumatoid Factor (RF) Positive PJIA
Rheumatoid Factor (RF) Negative PJIA
By Drug Type:
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Biologic Response Modifiers
Corticosteroids
By Line of Therapy:
First-line of therapy
Second-line of therapy
By Type of Therapy:
Monotherapy
Combination Therapy
Market Dynamics: Explored in the report
Untreated Prevalent Pool of Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Growing Clinical Trial Activities: Development in new generation treatment options such as targeted therapies, biological therapies revolutionizing the management of Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Conducive reimbursement, pricing strategies, and market access ecosystems
Huge medical unmet need
Patient Advocacy and Education
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Lack of timely diagnosis
Research gap
Treatment compliance and adherence
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
5-Europe Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
AbbVie
Pfizer
Roche/Genentech
Bristol Myers Squibb
Eli Lilly
Novartis
UCB
Regeneron Pharmaceuticals
J&J Pharmaceuticals
Others
Reason to buy this report:
Fostering Understanding on Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
